SCID Models Market garnered a revenue of USD 43.50 Million in the year 2019 globally and has been foreseen to yield USD 61.95 Million by the year 2027 at a compound annual growth (CAGR) of 4.6% over the forecast period. Researchers are investigating the development of severe combined immunodeficient (SCID) pig models for translational brazil rcs data cancer modelling. Several severe combined immunodeficient (SCID) pig models have been developed or genetically created in the previous decade. SCID pigs with NK cells but lacking in T and B cells, or defective in NK, T, and B cells for research investigations, have mutations in the ARTEMIS, IL2RG, or RAG1/2 genes, or combinations thereof.
The report ” Global SCID Model Market, By Model (Mouse, Pigs and Other), By Treatment (Stem Cell Therapy, Gene Therapy, and Enzyme Therapy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Trends, Analysis, and Forecast till 2030’’
Key Highlights:
• In 2021, PhoenixBio Co., Ltd. established a partnership with Inotiv, Inc. (“Inotiv”) to provide pre-clinical research services using the PXB-mouse (cDNA-uPA/SCID mouse model with a humanised liver). Through Inotiv’s contract study site in North America, clients will have the option of using the PXB-mouse for research, and PhoenixBio’s ability to meet the growing demand for services using its proprietary animal model will be expanded.